SMMT241220P18500
- 0.60
- -0.35-36.84%
Summit Therapeutics Newsroom
Summit Therapeutics Initiated at Overweight by Wells Fargo
Wells Fargo Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $30
Summit Therapeutics Analyst Ratings
Jefferies Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $31
Summit Therapeutics Initiated With a Buy at Jefferies
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Summit Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target
Strategic Position and Acquisition Interest Bolster Buy Rating for Summit Therapeutics
JMP Securities Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $32
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $44
IBRX Soars 47% on Initial Trials For Cell Therapy Product
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $45 Price Target
Buy Rating Affirmed for Summit Therapeutics Amid Promising Clinical Trials and Regulatory Progress
Citi Downgrades Summit Therapeutics(SMMT.US) to Hold Rating, Raises Target Price to $23